Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Sales | 486,030 | 452,117 | 476,784 | 429,485 | 502,069 |
| Cost of Goods | 120,166 | 126,138 | 188,793 | 97,967 | 111,374 |
| Gross Profit | 365,864 | 325,979 | 287,991 | 331,518 | 390,695 |
| Operating Expenses | 340,944 | 377,632 | 344,725 | 373,430 | 286,108 |
| Operating Income | 25,086 | -51,515 | -55,941 | -40,945 | 104,961 |
| Interest Expense | 3,804 | 4,749 | 9,597 | 8,048 | 6,915 |
| Other Income | 1,946 | 9,404 | 4,322 | 6,720 | 3,306 |
| Pre-tax Income | 23,228 | -46,860 | -61,216 | -42,273 | 101,352 |
| Income Tax | 5,857 | -63,888 | -846,019 | -13,090 | 19,971 |
| Net Income Continuous | 17,371 | 17,028 | 784,803 | -29,183 | 81,381 |
| Net Income | $17,371 | $17,028 | $784,803 | $-29,183 | $81,381 |
| EPS Basic Total Ops | 0.10 | 0.10 | 4.33 | -0.16 | 0.45 |
| EPS Basic Continuous Ops | 0.10 | 0.10 | 4.33 | -0.16 | 0.45 |
| EPS Diluted Total Ops | 0.09 | 0.21 | 4.01 | -0.16 | 0.44 |
| EPS Diluted Continuous Ops | 0.09 | 0.21 | 3.97 | -0.16 | 0.43 |
| EBITDA(a) | $53,742 | $-23,765 | $-29,170 | $-15,751 | $130,985 |